Immuneering Presented Preclinical Data At AACR annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors

4/9/24 12:04:39 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $IMRX alert in real time by email

Globe Newswire

- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone -

- Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting -

- Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 -

Get the next $IMRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMRX

Date	Price Target	Rating	Analyst
3/15/2024	$20.00 → $15.00	Buy	Needham
3/15/2024		Outperform → Market Perform	TD Cowen
3/15/2024	$16.00 → $3.00	Buy → Hold	Jefferies
12/1/2023	$20.00	Buy	Needham
6/26/2023	$25.00	Outperform	Oppenheimer
4/19/2023	$5.00 → $14.00	Underweight → Equal-Weight	Morgan Stanley
4/19/2023	$10.00 → $20.00	Neutral → Buy	Mizuho
3/30/2023	$10.00	Neutral	Mizuho

More analyst ratings

$IMRX
Financials

Live finance-specific insights

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper res
9/12/24 4:05:00 PM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, supporting goal of Universal-RAS activity - - Target lesion regression observed in over half of patients treated with IMM-1-104 at 320mg or 240mg QD, with best individual lesion regression of -35.7% and best RECIST sum of longest diameters (SLD) of -18.9%, both at 320mg - - Candidate RP2D of 320 mg QD supported by tolerability, PK/PD, ctDNA results & initial anti-tumor activity - - Phase 2a portion of the study underway with three monotherapy and two combin
3/14/24 7:00:00 AM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
Data presented at AACR Annual Meeting support IMM-1-104's potential to address a broad population of patients with RAS mutant tumorsIMM-1-104 well tolerated with no dose limiting toxicities (DLTs) or serious adverse events (SAEs) observed First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predictedPharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected Study timeline accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024Investor call to be held today at 9.00 a.m. ET CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIR
4/18/23 9:00:00 AM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care

$IMRX
Press Releases

Fastest customizable press release news feed in the world

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
- Immuneering recently announced positive initial Phase 2a data, including complete and partial responses, with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients - -Initial data from at least one additional arm of the Phase 2a portion of the Company's Phase 1/2a trial is expected by year-end - CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IMM-1-104 in the treatment of p
10/15/24 8:00:00 AM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment - - Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel - - Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper res
9/12/24 4:05:00 PM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from September 4-6, 2024, to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Hall, Chief Scientific Officer, Harold "E.B." Brakewood, Chief Business Officer, Michael Bookman, Chief Legal Officer and Secretary an
8/29/24 8:00:00 AM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care

$IMRX
Leadership Updates

Live Leadership Updates

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Either Treatment Alone - - First Patient Dosed in Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations; Initial PK, PD and safety data expected in 2024 - CAMBRIDGE
5/7/24 4:05:00 PM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors. "On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board," said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. "Tom's extensive experience developing new medicines, including 25 years guiding drug discovery, development and commercialization
3/12/24 8:00:00 AM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting - -First demonstration of novel deep cyclic inhibition mechanism in humans, with IMM-1-104 achieving significant levels of PK Cmax and a half-life of approximately two hours as predicted - - Study timeline for IMM-1-104 accelerated: recommended Phase 2 dose (RP2D) now expected in early 2024- - Pharmacodynamic data support potential to evaluate preliminary efficacy sooner than expected - - Completed $30 million underwritten offering; Projected cash runway extended into 2025 - CAMBRIDGE, Mass., May
5/4/23 4:05:00 PM ET
$IMRX
Biotechnology: Pharmaceutical Preparations
Health Care

Immuneering Presented Preclinical Data At AACR annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors

Chat with this insight

Recent Analyst Ratings for $IMRX

$IMRX Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Schall Thomas J. bought $7,385 worth of shares (2,900 units at $2.55) (SEC Form 4)

Feinberg Peter bought $63,713 worth of shares (25,000 units at $2.55), increasing direct ownership by 29% to 111,766 units (SEC Form 4)

Brakewood Harold Eugene bought $10,015 worth of shares (3,900 units at $2.57) (SEC Form 4)

$IMRX Financials

Live finance-specific insights

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

$IMRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

SEC Form SC 13G/A filed by Immuneering Corporation (Amendment)

$IMRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Accounting Officer Morales Mallory was granted 4,458 shares, increasing direct ownership by 54% to 12,736 units (SEC Form 4)

SEC Form 4 filed by Director Schall Thomas J.

SEC Form 4 filed by Director Keating Laurie

$IMRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$IMRX Market Insights

Live Market Insights

Needham reiterated coverage on Immuneering Corporation with a new price target

Immuneering Corporation downgraded by TD Cowen

Immuneering Corporation downgraded by Jefferies with a new price target

12 Health Care Stocks Moving In Tuesday's After-Market Session

Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Immuneering Q1 EPS $(0.49) Misses $(0.46) Estimate

$IMRX SEC Filings

Amendment: Immuneering Corporation filed SEC Form 8-K: Leadership Update

Immuneering Corporation filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by Immuneering Corporation

$IMRX Press Releases

Fastest customizable press release news feed in the world

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

$IMRX Leadership Updates

Live Leadership Updates

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

Recent Analyst Ratings for
$IMRX

$IMRX
Insider Purchases

$IMRX
Financials

$IMRX
Large Ownership Changes

$IMRX
Insider Trading

$IMRX
Analyst Ratings

$IMRX
Market Insights

$IMRX
SEC Filings

$IMRX
Press Releases

$IMRX
Leadership Updates